NCT04789148View on ClinicalTrials.gov

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Vasopressin Deficiency
Interventions
DRUG

Intranasal Oxytocin (IN-OXT)

6 IU single dose

DRUG

Intranasal Oxytocin (IN-OXT)

IN-OXT 6 IU three times a day for 2 weeks

DRUG

Placebo

Intranasal placebo three times a day for 2 weeks

DRUG

Intranasal Oxytocin (IN-OXT)

24 IU single dose

DRUG

Placebo

placebo single dose

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Neuroendocrine Unit, Boston

All Listed Sponsors
collaborator

Tonix Pharmaceuticals, Inc.

INDUSTRY

lead

Elizabeth Austen Lawson

OTHER